A newly defined human B cell differentiation antigen, designated as BDA, has been defined and partially characterized. BDA is expressed on normal human B cells and lymphocytic leukemia cells at all stages of known differentiation (pre-B cells to plasma cells). It is distinct from DR (Ia-like) determinants and other known B cell surface constituents.


This investigation was supported by grants from the Medical Research Service of the Veteran's Administration, The American Cancer Society, and The National Institutes of Health (CA13148, CA 126672, AI 13154). This is publication No. 1485 from the Department of Molecular Immunology, Scripps Clinic and Research Foundation.

This content is only available via PDF.